Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 371-381 , May 2007

Differences in binding of 99mTc-disintegrins to integrin αvβ3 on tumor and vascular cells

  • Linda C. Knight

      Affiliations

    • Radiology Department, Temple University School of Medicine, Philadelphia, PA 19140, USA
    • Corresponding Author InformationCorresponding author. Department of Radiology, Temple University School of Medicine, Philadelphia, PA 19140, USA. Tel.: +1 215 707 4940; fax: +1 215 707 8110.
    • ,
  • Jan E. Romano

      Affiliations

    • Radiology Department, Temple University School of Medicine, Philadelphia, PA 19140, USA
    • ,
  • Stephen C. Cosenza

      Affiliations

    • Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA 19140, USA
    • ,
  • Nabisa M. Iqbal

      Affiliations

    • Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA 19140, USA
    • ,
  • Cezary Marcinkiewicz

      Affiliations

    • Neuroscience Department, Temple University School of Medicine, Philadelphia, PA 19140, USA

Received 6 December 2006 ,Revised 30 January 2007 ,Accepted 16 February 2007.

References 

  1. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol. 1993;5:864–868
  2. Suehiro K, Smith JW, Plow EF. The ligand recognition specificity of β3 integrins. J Biol Chem. 1996;271:10365–10371
  3. Shattil SJ. Function and regulation of the β3 integrins in hemostasis and vascular biology. Thromb Haemost. 1995;74:149–155
  4. Brooks PC, Cheresh DA, Clark AF. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569–571
  5. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of the integrins. Med Res Rev. 1994;14:195–228
  6. Albelda SM, Mette SA, Elder DE, et al. Integrin distribution in malignant melanoma: association of the beta(3) subunit with tumor progression. Cancer Res. 1990;50:6757–6764
  7. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alpha(v)beta(3) integrin. Adhesion mechanism for transformed glial cells. J Clin Invest. 1991;88:1924–1932
  8. Beauvais DM, Burbach BJ, Rapraeger AC. The syndecan-1 ectodomain regulates avb3 integrin activity in human mammary carcinoma cells. J Cell Biol. 2004;167:171–181
  9. Cheresh DA, Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibronectin, and von Willebrand factor. J Biol Chem. 1987;262:17703–17711
  10. Haubner R, Wester H-J, Reuning U, et al. Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061–1071
  11. Juliano D, Wang Y, Marcinkiewicz C, Rosenthal LA, Stewart GJ, Niewiarowski S. Disintegrin interaction with alpha V beta 3 integrin on human umbilical vein endothelial cells: expression of ligand-induced binding site on beta 3 subunit. Exp Cell Res. 1996;225:132–142
  12. Pfaff M, McLane MA, Beviglia L, Niewiarowski S, Timpl R. Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins alphaIIb beta3, alphaV beta3 and alpha5 beta1 and in cell adhesion inhibition. Cell Adhes Commun. 1994;2:491–501
  13. Scarborough RM, Rose JW, McNaughton MA, et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem. 1993;268:1058–1065
  14. Gould RJ, Polokoff MA, Friedman PA, et al. Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med. 1990;195:168–171
  15. Niewiarowski S, McLane MA, Kloczewiak M, Stewart GJ. Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors. Semin Hematol. 1994;31:289–300
  16. Knight LC, Baidoo KE, Romano JE, Gabriel JL, Maurer AH. Imaging pulmonary emboli and deep venous thrombi with 99mTc-labeled bitistatin, a platelet-binding polypeptide from viper venom. J Nucl Med. 2000;41:1056–1064
  17. McQuade P, Knight LC, Welch MJ. Evaluation of 64Cu and 125I-radiolabeled bitistatin as potential agents for targeting αvβ3 integrins in tumor angiogenesis. Bioconjug Chem. 2004;15:988–996
  18. Knight LC, Romano JE. Functional expression of bitistatin, a disintegrin with potential use in molecular imaging of thromboembolic disease. Protein Expr Purif. 2005;39:307–319
  19. Dennis MS, Henzel WJ, Pitti RM, et al. Platelet glycoprotein IIb–IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci U S A. 1989;87:2471–2475
  20. Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA. Echistatin: a potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem. 1988;263:19827–19832
  21. Calvete JJ, Wang Y, Mann K, Schafer W, Niewiarowski S, Stewart GJ. The disulfide bridge pattern of snake venom disintegrins, flavoridin and echistatin. FEBS Lett. 1992;309:316–320
  22. Calvete JJ, Moreno-Murciano MP, Theakston RDG, Kisiel DG, Marcinkiewicz C. Snake venom disintegrins: novel dimeric disintegrins and structural diversification by disulphide bond engineering. Biochem J. 2003;372:725–734
  23. Abrams MJ, Juweid M, tenKate CI, et al. Technetium-99m-human polyclonal IgG radiolabeled with the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 1990;31:2022–2028
  24. King T, Zhao S, Lan T. Preparation of protein conjugates via intermolecular hydrazone linkage. Biochemistry. 1986;25:5774–5779
  25. Larsen SK, Solomon HF, Caldwell G, Abrams MJ. [99mTc]Tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates. Bioconjug Chem. 1995;6:635–638
  26. Pfaff M, Tangemann K, Müller B, et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by αIIbβ3, αvβ3 and α5β1 integrins. J Biol Chem. 1994;269:20233–20238
  27. Brassard D, Maxwell E, Malkowski M, Nagabhushan T, Kumar C, Armstrong L. Integrin alphavbeta3-mediated activation of apoptosis. Exp Cell Res. 1999;33–45
  28. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct av integrins. Science. 1995;270:1500–1502
  29. van Hagen PM, Breeman WAP, Bernard HF, Schaar M, Krenning EP, de Jong M. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer. 2000;8:186–198
  30. McLane MA, Vijay-Kumar S, Marcinkiewicz C, Calvete JJ, Niewiarowski S. Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of α IIbβ3 and αvβ3 integrins. FEBS Lett. 1996;391:139–143
  31. Wierzbicka-Patynowski I, Niewiarowski S, Marcinkiewicz C, Calvete JJ, Marcinkiewicz MM, McLane MA. Structural requirements of echistatin for the recognition of αvβ3 and α5β1 integrins. J Biol Chem. 1999;274:37809–37814
  32. Jones JI, Prevette T, Gockerman A, Clemmons DR. Ligand occupancy of the αvβ3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci U S A. 1996;93:2482–2487
  33. Tselepis V, Green LJ, Humphries MJ. An RGD to LDV motif conversion within the disintegrin kistrin generates an integrin antagonist that retains potency but exhibits altered receptor specificity. J Biol Chem. 1997;272:21341–21348
  34. Sheu J-R, Yen M-H, Kan Y-C, Hung W-C, Chang P-T, Luk H-N. Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-αvβ3 integrin monoclonal antibody. Biochim Biophys Acta. 1997;1336:445–454
  35. Kok RJ, Schraa AJ, Bos EJ, et al. Preparation and functional evaluation of RGD-modified proteins as αvβ3 integrin directed therapeutics. Bioconjug Chem. 2002;13:128–135
  36. Knight LC, Maurer AH, Romano JE. Comparison of iodine-123-disintegrins for imaging thrombi and emboli in a canine model. J Nucl Med. 1996;37:476–482
  37. Calvete J, Schrader M, Raida M, McLane MA, Romero A, Niewiarowski S. The disulphide bond pattern of bitistatin, a disintegrin isolated from the venom of the viper Bitis arietans. FEBS Lett. 1997;416:197–202
  38. McLane MA, Marcinkiewicz C, Vijay-Kumar S, Wierzbicka-Patynowski I, Niewiarowski S. Viper venom disintegrins and related molecules. Proc Soc Exp Biol Med. 1998;219:109–119
  39. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, et al. Barbourin, a GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991;266:9359–9362
  40. Knight LC, Romano JE, Gabriel JL. Selection of radiolabeling sites by site-directed mutagenesis. J Labelled Compd Radiopharm. 2003;46:S24
  41. Marcinkiewicz C, Vijay-Kumar S, McLane MA, Niewiarowski S. Significance of RGD loop and C-terminal domain of echistatin for recognition of αIIbβ3 and αvβ3 integrins and expression of ligand-induced binding site. Blood. 1997;90:1565–1575
  42. Rahman S, Aitken A, Flynn G, Formstone C, Savidge GF. Modulation of RGD sequence motifs regulates disintegrin recognition of αIIbβ3 and α5β1 integrin complexes. Biochem J. 1998;335:247–257
  43. Ly DP, Zazzali KM, Corbett SA. De novo expression of the integrin α5β1 regulates αvβ3-mediated adhesion and migration on fibrinogen. J Biol Chem. 2003;278:21878–21885

PII: S0969-8051(07)00046-7

doi: 10.1016/j.nucmedbio.2007.02.004

Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 371-381 , May 2007

Article Tools

* Image Usage & Resolution